Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natamycin + voriconazole
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
A combination of two antifungal drugs used primarily for the treatment of fungal keratitis. Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, while voriconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent 14α-lanosterol demethylation. The combination has shown synergistic interactions in vitro against resistant Fusarium species, though clinical evidence for superiority over monotherapy is mixed.
02
Targets
ErgosterolCYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on natamycin + voriconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natamycin + voriconazole.